Cantor Fitzgerald lowered the firm’s price target on Humana (HUM) to $290 from $395 and keeps a Neutral rating on the shares. Cantor is less confident than sentiment appears that all the risks are baked into Humana’s stock, and the firm remains on the sidelines as there are a number of items that need to be executed on to make the firm more comfortable, the analyst tells investors in a research note. While management appears to be prioritizing a conservative guidance posture, the firm believes there needs to be more clarity on the out-years despite the clean quarter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HUM:
- Humana price target raised to $253 from $250 at Barclays
- Humana’s Medicare Advantage Star Ratings Drop: Legal Battle Looms Over 2025 Projections and Potential Revenue Impact
- Humana Inc. Reports Mixed Q3 2024 Results
- HUM Earnings: Humana Reports Better-than-Expected Q3 Results, Updates Outlook
- Humana: 3% margin target for 2027 ‘realistic,’ but ‘at risk’
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
